Cargando…
Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863335/ https://www.ncbi.nlm.nih.gov/pubmed/36675640 http://dx.doi.org/10.3390/jcm12020712 |
_version_ | 1784875308327895040 |
---|---|
author | Lee, Yoonseok Bae, Seryun Kim, Ji Hoon Kwak, Minjung Jeon, So Yeon Kim, Taehyung Yim, Sun Young Lee, Young-Sun Jung, Young Kul Seo, Yeon Seok Yim, Hyung Joon Yeon, Jong Eun Byun, Kwan Soo |
author_facet | Lee, Yoonseok Bae, Seryun Kim, Ji Hoon Kwak, Minjung Jeon, So Yeon Kim, Taehyung Yim, Sun Young Lee, Young-Sun Jung, Young Kul Seo, Yeon Seok Yim, Hyung Joon Yeon, Jong Eun Byun, Kwan Soo |
author_sort | Lee, Yoonseok |
collection | PubMed |
description | Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from healthy controls. Methods: Overall, 206 subjects were prospectively enrolled. LC was diagnosed based on liver stiffness levels (>11 kPa) measured using transient elastography. Serum AsAGP levels were measured using an antibody-lectin sandwich immunoassay. We investigated the diagnostic performance by comparing serum AsAGP levels among healthy control, CHB, and CHB with LC groups. Sensitivity, specificity, and optimal AsAGP cut-off values were also calculated. Results: Serum AsAGP levels were significantly different between healthy controls, CHB patients, and CHB patients with LC (1.04 ± 0.31 µg/mL, 1.12 ± 0.34 µg/mL, 1.51 ± 0.43 µg/mL respectively; p < 0.001). Serum AsAGP levels positively correlated with liver stiffness (r = 0.46, p < 0.001). AUROC of healthy control versus CHB with LC was 0.821 (p < 0.001, optimal cut-off 1.036 µg/mL). AUROC of healthy control versus CHB was 0.624 (p = 0.049, optimal cut-off level 0.934 µg/mL). AUROC of CHB versus CHB with LC was 0.765, (p < 0.001, optimal cut-off 1.260 µg/mL). Conclusions: Serum AsAGP levels in CHB patients with LC were significantly higher than those in healthy controls and CHB patients. AsAGP levels showed good diagnostic performance in predicting advanced fibrosis and cirrhosis, which suggests a potential role as a biomarker for predicting the progression of liver disease in CHB. |
format | Online Article Text |
id | pubmed-9863335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98633352023-01-22 Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study Lee, Yoonseok Bae, Seryun Kim, Ji Hoon Kwak, Minjung Jeon, So Yeon Kim, Taehyung Yim, Sun Young Lee, Young-Sun Jung, Young Kul Seo, Yeon Seok Yim, Hyung Joon Yeon, Jong Eun Byun, Kwan Soo J Clin Med Article Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from healthy controls. Methods: Overall, 206 subjects were prospectively enrolled. LC was diagnosed based on liver stiffness levels (>11 kPa) measured using transient elastography. Serum AsAGP levels were measured using an antibody-lectin sandwich immunoassay. We investigated the diagnostic performance by comparing serum AsAGP levels among healthy control, CHB, and CHB with LC groups. Sensitivity, specificity, and optimal AsAGP cut-off values were also calculated. Results: Serum AsAGP levels were significantly different between healthy controls, CHB patients, and CHB patients with LC (1.04 ± 0.31 µg/mL, 1.12 ± 0.34 µg/mL, 1.51 ± 0.43 µg/mL respectively; p < 0.001). Serum AsAGP levels positively correlated with liver stiffness (r = 0.46, p < 0.001). AUROC of healthy control versus CHB with LC was 0.821 (p < 0.001, optimal cut-off 1.036 µg/mL). AUROC of healthy control versus CHB was 0.624 (p = 0.049, optimal cut-off level 0.934 µg/mL). AUROC of CHB versus CHB with LC was 0.765, (p < 0.001, optimal cut-off 1.260 µg/mL). Conclusions: Serum AsAGP levels in CHB patients with LC were significantly higher than those in healthy controls and CHB patients. AsAGP levels showed good diagnostic performance in predicting advanced fibrosis and cirrhosis, which suggests a potential role as a biomarker for predicting the progression of liver disease in CHB. MDPI 2023-01-16 /pmc/articles/PMC9863335/ /pubmed/36675640 http://dx.doi.org/10.3390/jcm12020712 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Yoonseok Bae, Seryun Kim, Ji Hoon Kwak, Minjung Jeon, So Yeon Kim, Taehyung Yim, Sun Young Lee, Young-Sun Jung, Young Kul Seo, Yeon Seok Yim, Hyung Joon Yeon, Jong Eun Byun, Kwan Soo Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
title | Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
title_full | Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
title_fullStr | Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
title_full_unstemmed | Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
title_short | Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
title_sort | diagnostic efficacy of serum asialo α1-acid glycoprotein levels for advanced liver fibrosis and cirrhosis in patients with chronic hepatitis b compared to that in healthy subjects: a prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863335/ https://www.ncbi.nlm.nih.gov/pubmed/36675640 http://dx.doi.org/10.3390/jcm12020712 |
work_keys_str_mv | AT leeyoonseok diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT baeseryun diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT kimjihoon diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT kwakminjung diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT jeonsoyeon diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT kimtaehyung diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT yimsunyoung diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT leeyoungsun diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT jungyoungkul diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT seoyeonseok diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT yimhyungjoon diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT yeonjongeun diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy AT byunkwansoo diagnosticefficacyofserumasialoa1acidglycoproteinlevelsforadvancedliverfibrosisandcirrhosisinpatientswithchronichepatitisbcomparedtothatinhealthysubjectsaprospectivestudy |